Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

plasmapheresis and anti-CD20 monoclonal antibody therapy, are occasionally employed. Immunosuppressants used to treat pemphigus include azathioprine, cyclophosphamide, cyclosporine, mycophenolate ...

Rituximab, a monoclonal antibody directed against CD20, has been successfully used ... Only IgM levels decreased significantly; levels of anti-double-stranded DNA antibodies declined in all ...

It licensed the compound, an anti-CD20 mAb, to London-based GlaxoSmithKline in late 2006. The entire development process, from generating a hybridoma cell line to final approval, took seven years ...

Bleakley Financial Group LLC purchased a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX – Free Report) in the 4th quarter, Holdings Channel.com reports. The fund purchased 8,140 shares of the ...

Monoclonal antibody to CD25, results in expansion of ... Concerns raised about increased infection risk and transaminitis. Anti-CD20 agents: B lymphocyte depletion: Rituximab no longer being ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...